Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Hypoxia 4 Melanoma 3 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 Tongue Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Skin Neoplasms 1 Sarcoma 1 Rectal Neoplasms 1 Neoplasms 1 Immune System Diseases 1 Head and Neck Neoplasms 1

Interventions

pembrolizumab 24 Nivolumab 23 aldesleukin 21 Cyclophosphamide 20 Ipilimumab 17 Interleukin-2 17 fludarabine 15 fludarabine phosphate 14 cemiplimab 12 Radiotherapy 7 Fluorouracil 7 Biopsy 7 dabrafenib 6 Surveys and Questionnaires 6 Dacarbazine 6 trametinib 5 binimetinib 5 Vemurafenib 5 Temozolomide 5 Surgical Procedures, Operative 5 Sirolimus 5 Radiation 5 Blood Specimen Collection 5 Aminolevulinic Acid 5 sonidegib 4 encorafenib 4 Photochemotherapy 4 Mohs Surgery 4 HhAntag691 4 Educational Status 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Skin Neoplasms × pimonidazole × Clear all

NCT02061007 2016-05-09

Biomarker Correlates of Hypoxia in Metastatic Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Withdrawn

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡